Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer - Related Studies

Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

This study is ongoing, but not recruiting participants.

Study NCT00020254. Last updated on November 12, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Prostate Cancer

2	Additional conditions recognized in this trial
		Prostatic Neoplasms

3	More general conditions related to this trial
		Genital Diseases, Male
		Genital Neoplasms, Male
		Neoplasms
		Neoplasms by Site
		Prostatic Diseases
		Urogenital Neoplasms

4	Interventions listed in this trial
		aldesleukin
		nilutamide
		recombinant vaccinia-B7.1 vaccine
		sargramostim

5	More general drug interventions related to this trial
		Androgen Antagonists
		Anti-HIV Agents
		Anti-Infective Agents
		Anti-Retroviral Agents
		Antineoplastic Agents
		Antiviral Agents
		Hormone Antagonists
		Hormones, Hormone Substitutes, and Hormone Antagonists
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		NCI - Center for Cancer Research-Medical Oncology
		National Cancer Institute (NCI)